Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting

Schedule of certain segment information

	Three Months Ended March 31,
	2025		2024
Grant and award revenue	$	491	$	966
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		(440)		1,834
AP-PA02: Cystic Fibrosis		11		97
AP-SA02: Bacteremia		652		83
AP-SA02: Prosthetic Joint Infection		1		7
Expenses not allocated by projects		520		632
Total external research and development expenses		744		2,653
Research and development personnel expenses		2,313		2,613
Other research and development expenses		2,372		2,750
Total research and development expenses		5,429		8,016
General and administrative expenses:
General and administrative personnel expenses		1,401		934
Other general and administrative expenses		1,852		2,244
Total general and administrative expenses		3,253		3,178
Total operating expenses		8,682		11,194
Operating loss		(8,191)		(10,228)
Other income (expense), net		1,660		(14,793)
Net loss	$	(6,531)	$	(25,021)